Ionara Bio is developing novel, proprietary small molecules that target and block the TRPV2 channel—a key driver of inflammatory responses, particularly those involving macrophages, that impair cardiac structure and function following acute myocardial infarction (AMI). The company’s lead candidate, a first-in-class TRPV2 inhibitor, is designed to improve cardiac function and reduce pathological cardiac fibrosis, ultimately leading to significantly enhanced post-AMI recovery.